SEARCH

SEARCH BY CITATION

References

  • 1
    Wingo PA, Tong T, Bolden S: Cancer statistics: 1995. CA Cancer J Clin 1995; 45: 830.
  • 2
    Einhorn N, Bast RC Jr Knapp RC, et al: Preoperative evaluation of serum CA 125 levels in patients with primary epithelial ovarian cancer. Obstet Gynecol 1986; 67: 414416.
  • 3
    Silverberg E, Boring C, Squires TS: Cancer statistics, 1990. CA 1990; 40: 926.
  • 4
    Teneriello MG, Park RC: Early detection of ovarian cancer. CA Cancer J Clin 1995; 45: 7187.
  • 5
    National Institutes of Health: Consensus conference on ovarian cancer, April, 1994.
  • 6
    Lynch HT, Lynch JF: Hereditary ovarian cancer. Hematol Oncol Clin North Am 1992; 6: 783811.
  • 7
    Young RC, Fuks Z, Hoskins WJ: Cancer of the ovary, in DeVitaVTJr, HellmanS, RosenbergSA (eds): Cancer: Principles and Practice of Oncology, ed. 3. Philadelphia, JB Lippincott, 1989.
  • 8
    Young RC, Decker DG, Wharton JT, et al: Staging laparotomy in early ovarian cancer. JAMA 1983; 250: 30723076.
  • 9
    McGowan L, Lesher LP, Norris HJ, Barnett M: Misstaging of ovarian cancer. Obstet Gynecol 1985; 65: 568572.
  • 10
    Nguyen HN, Averette HE, Hoskins W, et al: National survey of ovarian carcinoma: Part V. The impact of physician's specialty on patients' survival. Cancer 1993; 72: 36633670.
  • 11
    Bagley CM Jr Young RC, Schein PS, et al: Ovarian carcinoma metastatic to the diaphragm: Frequently undiagnosed at laparotomy: A preliminary report. Am J Obstet Gynecol 1973; 116: 397400.
  • 12
    Burghardt E, Pickel H, Holzer E, Lahousen M: The significance of lymphadenectomy in therapy of ovarian carcinoma. Am J Obstet Gynecol 1983; 146: 111112.
  • 13
    Keettel WC, Pixley EE, Buchsbaum HJ: Experience with peritoneal cytology in the management of gynecologic malignancies. Am J Obstet Gynecol 1974; 120: 174182.
  • 14
    Knapp RC, Friedman EA: Aortic lymph node metastases in early ovarian cancer. Am J Obstet Gynecol 1974; 119: 10131017.
  • 15
    Hreshchyshyn MM, Park RC, Blessing JA, et al: The role of adjuvant therapy in Stage I ovarian cancer. Am J Obstet Gynecol 1980; 138: 139145.
  • 16
    Young RC, Walton LA, Ellenberg SS, et al: Adjuvant therapy in Stage I and Stage II epithelial ovarian cancer: Results of two prospective, randomized trials. N Engl J Med 1990; 322: 10211027.
  • 17
    Bolis G, Marsoni S, Chiari S, et al: Cooperative randomized clinical trial for stage I ovarian cancer, in ContePF et al (eds): Multimodal Treatment of Ovarian Cancer. New York, Raven Press, 1989, pp 8186.
  • 18
    Dembo AJ, Bush RS: Choice of postoperative therapy based on prognostic factors. Int J Radiat Oncol Biol Phys 1982; 8: 893897.
  • 19
    Dembo AJ, Davy M, Stenwig AE, et al: Prognostic factors in patients with stage I epithelial ovarian cancer. Obstet Gynecol 1990; 75: 263273.
  • 20
    Vergote IB, Vergote-De Vos LN, Abeler VM, et al: Randomized trial comparing cisplatin with radioactive phosphorus or whole-abdomen irradiation as adjuvant treatment of ovarian cancer. Cancer 1992; 69: 741749.
  • 21
    Bush RS, Allt WE, Beale FA, et al: Treatment of epithelial carcinoma of the ovary: Operation, irradiation and chemotherapy. Am J Obstet Gynecol 1977; 127: 692704.
  • 22
    Dembo AJ, Bush RS, Beale FA, et al: Ovarian carcinoma: Improved survival following abdominopelvic irradiation in patients with a completed pelvic operation. Am J Obstet Gynecol 1979; 134: 793800.
  • 23
    Sell A, Bertelsen K, Andersen JE, et al: Randomized study of whole-abdominal irradiation versus pelvic irradiation plus cyclophosphamide in treatment of early ovarian cancer. Gynecol Oncol 1990; 37: 367373.
  • 24
    Klaassen D, Shelly W, Starreveld A, et al: Early stage ovarian cancer: A randomized clinical trial comparing whole abdominal radiotherapy, melphalan and intraperitoneal chromic phosphate: A National Cancer Institute of Canada Clinical Trials Group report. J Clin Oncol 1988; 6: 12541263.
  • 25
    Young RC, Knapp RC, Fuks ZV, DiSaia PJ: Cancer of the ovary. in DeVitaVTJr, HellmanS, RosenbergSA (eds): Cancer: Principles and Practice of Oncology, ed. 2. New York, JB Lippincott, 1985, pp 10831117.
  • 26
    Richardson GS, Scully RE, Nikrui N, Nelson JH Jr: Common epithelial cancer of the ovary. N Engl J Med 1985; 312: 415424.
  • 27
    Bolis G, Torri V, Babilonti L, et al: Multicenter controlled trial in patients with stage I epithelial ovarian cancer. Proceedings of the International Gynecologic Cancer Society 1991; 3: 16.
  • 28
    Vergote IB, Vergote-De Vos LN, Abeler VM, et al: Randomized trial comparing cisplatin with radioactive phosphorus or whole-abdomen irradiation as adjuvant treatment of ovarian cancer. Cancer 1992; 69: 741749.
  • 29
    Cannistra SA: Cancer of ovary. N Engl J Med 1993; 329: 15501559.
  • 30
    Hoskins WJ, Rubin SC: Surgery in the treatment of patients with advanced ovarian cancer. Semin Oncol 1991; 18: 213221.
  • 31
    Neijt JP, ten Bokkel Huinink WW, van der Burg ME, et al: Long-term survival in ovarian cancer: Mature data from the Netherlands joint study group for ovarian cancer. Eur J Cancer 1991; 27: 13671372.
  • 32
    Omura GA, Brady MF, Homesley HD, et al: Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: The Gynecologic Oncology Group experience. J Clin Oncol 1991; 9: 11381150.
  • 33
    Marsoni S, Torri V, Valsecchi MG, et al: Prognostic factors in advanced epithelial ovarian cancer. Br J Cancer 1990; 62: 444450.
  • 34
    van Houwelingen JC, ten Bokkel Huinink WW, van der Burg ME, et al: Predictability of the survival of patients with advanced ovarian cancer. J Clin Oncol 1989; 7: 769773.
  • 35
    Luesley D, Lawton F, Blackledge G, et al: Failure of second-look laparotomy to influence survival in epithelial ovarian cancer. Lancet 1988; 2: 599603.
  • 36
    Copeland LJ, Vaccarello L, Lewandowski GS: Second-look laparotomy in epithelial ovarian cancer. Obstet Gynecol Clin North Am 1994; 21: 155166.
  • 37
    Thigpen JT, Blessing JA, Vance RB, et al: Chemotherapy in ovarian carcinoma: Present role and future prospects. Semin Oncol 1989; 16: 5865.
  • 38
    Neijt JP: Treatment of advanced epithelial ovarian cancer, in BlackledgeGRP, JordanJA, ShingletonHM (eds): Textbook of Gynecologic Oncology. London, WB Saunders, 1991, pp 176190.
  • 39
    Thigpen T: Single agent chemotherapy in the management of ovarian carcinoma, in AlbertsDS, SurwitE (eds): Ovarian Cancer. Boston, Martinus Nijhoff, 1985, pp 115146.
  • 40
    Williams CJ, Mead GM, Macbeth FR, et al: Cisplatin combination chemotherapy versus chlorambucil in advanced ovarian carcinoma: Mature results of a randomized trial. J Clin Oncol 1985; 3: 14551462.
  • 41
    Neijt JP, ten Bokkel Huinink WW, van der Burg ME, et al: Randomised trial comparing two combination chemotherapy regimens (HEXA-CAF vs CHAP-5) in advanced ovarian cancer. Lancet 1984; 2: 594600.
  • 42
    Omura GA, Blessing JA, Ehrlich CB, et al: A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian cancer. Cancer 1986; 57: 17251730.
  • 43
    Thigpen JT, Blessing JA, Vance RB, et al: Chemotherapy in ovarian carcinoma: Present role and future prospects. Semin Oncol 1989; 16: 5865.
  • 44
    Balvert-Locht HR, Coebergh JW, Hop WC, et al: Improved prognosis of ovarian cancer in The Netherlands during the period 1975–1985: A registry-based study. Gynecol Oncol 1991; 42: 38.
  • 45
    Williams CJ: Systematic overview of randomised trials in advanced ovarian carcinoma: Results and implications for future trials. Proceedings of the International Gynecologic Cancer Society 1991; 3: 49.
  • 46
    Alberts DS, Canetta R, Mason-Liddil N: Carboplatin in the first-line chemotherapy of ovarian cancer. Semin Oncol 1990; 17: 5460.
  • 47
    Swenerton KD: Cisplatin/cyclophosphamide vs carboplatin/cyclophosphamide in advanced ovarian cancer. Proceedings of the International Gynecologic Cancer Society 1991; 3: 44.
  • 48
    ten Bokkel Huinink WW, van den Burg ME, van Oosterom AT, et al: Long-term treatment results of a study comparing carboplatin with cisplatin in combination chemotherapy against advanced ovarian cancer. Proc Annu Meet Am Soc Clin Oncol 1991; 10: A647.
  • 49
    Mangioni C, Bolis G, Pecorelli S, et al: Randomized trial in advanced ovarian cancer comparing cisplatin and carboplatin. J Natl Cancer Inst 1989; 81: 14641471.
  • 50
    McGuire WP, Abeloff MD: Carboplatin substitution for cisplatin in the treatment of ovarian carcinoma: A word of caution. J Natl Cancer Inst 1989; 81: 14381439.
  • 51
    Edmonson JH, McCormack GM, Wieand HS, et al: Cyclophosphamide-cisplatin versus cyclophosphamide-carboplatin in stage III-IV ovarian carcinoma: A comparison of equally myelosuppressive regimens. J Natl Cancer Inst 1989; 81: 15001504.
  • 52
    Neijt JP: Ovarian cancer: Rethinking prognostic factors and chemotherapy. American Society of Clinical Oncologists Education Book, 1994, pp 214221.
  • 53
    McGuire WP: Primary treatment of epithelial ovarian malignancies. Cancer 1993; 71: 15411550.
  • 54
    Levin L, Hryniuk WM: Dose-intensity analysis of chemotherapy regimens in ovarian carcinoma. J Clin Oncol 1987; 5: 756767.
  • 55
    Kaye SB, Lewis CR, Paul J, et al: Randomised study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer. Lancet 1992; 340: 329333.
  • 56
    McGuire WP, Hoskins WJ, Brady MF, et al: A phase III trial of dose-intense (DI) vs standard-dose (DS) cisplatin (CDDP) and Cytoxan (CTX) in advanced ovarian cancer. Proc Annu Meet Am Soc Clin Oncol 1992; 11: A718.
  • 57
    Colombo N, Pittelli MR, Parma G, et al: Cisplatin (P) dose intensity in advance ovarian cancer (AOC): A randomized study of conventional dose (DC) vs dose-intense (DI) cisplatin monochemotherapy. Proc Annu Meet Am Soc Clin Oncol 1993; 12: A806.
  • 58
    Markman M: Salvage therapy in ovarian cancer: Is there a role for intraperitoneal drug delivery?. Gynecol Oncol 1993; 51: 8689.
  • 59
    Chabner BD: Taxol: Principles and Practice of Oncology: Updates. 1991; 5: 110.
  • 60
    McGuire WP, Rowinsky EK, Rosenshein NB, et al: Taxol: A unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 1989; 111: 273279.
  • 61
    Thigpen T, Blessing J, Ball H, et al: Phase II trial of Taxol as second-line therapy for ovarian carcinoma: A Gynecologic Oncology Group Study. Proc Annu Meet Am Soc Clin Oncol 1990; 9: 156.
  • 62
    Caldas C, McGuire WP: Taxol in epithelial ovarian cancer. Monogr Natl Cancer Inst 1993; 15: 155159.
  • 63
    Einzig AI, Wiernik PH, Sasloff J, et al: Phase II study and long-term follow-up of patients treated with Taxol for advanced ovarian adenocarcinoma. J Clin Oncol 1992; 10: 17481753.
  • 64
    Trimble EL, Adams JD, Vena D, et al: Paclitaxel for platinum refractory ovarian cancer: Results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103. J Clin Oncol 1993; 11: 24052410.
  • 65
    Sarosy G, Kohn E, Stone DA, et al: Phase I study of Taxol and granulocyte colony-stimulating factor in patients with refractory ovarian cancer. J Clin Oncol 1992; 10: 11651170.
  • 66
    Kohn EC, Sarosy G, Bicher A, et al: Dose-intense taxol: High response rate in patients with platinum-resistant recurrent ovarian cancer. J Natl Cancer Inst 1994; 86: 1824.
  • 67
    Link CJ Jr Bicher A, Kohn EC, et al: Flexible granulocyte colony-stimulating factor dosing in ovarian cancer patients who receive dose-intense taxol therapy. Blood 1994; 83: 11881192.
  • 68
    Swenerton K, Eisenhauer E, ten Bokkel Huinink W, et al: Taxol in relapsed ovarian cancer: High vs low dose and short vs long infusion. Proc Annu Meet Am Soc Clin Oncol 1993; 12: A810.
  • 69
    Rowinsky EK, Gilbert MR, McGuire WP, et al: Sequences of Taxol and cisplatin: A phase I and pharmacologic study. J Clin Oncol 1991; 9: 16921703.
  • 70
    Kudelka A, Edwards C, Freedman R, et al: An open phase II study to evaluate the efficacy and toxicity of topotecan administered iv as 5 daily infusions every 21 days to women with advanced epithelial ovarian carcinoma. Proc Annu Meet Am Soc Clin Oncol 1993; 12: A821.
  • 71
    Hansen HH, Lund B: Gemcitabine (2,2-difluorodeoxycytidine): A novel antineoplastic agent with activity in both lung and ovarian cancer. Ann Oncol 1992; 3: 161.